Kida Y - Among 99 patients with newly diagnosed ascites with cirrhosis, researcher intended to determine whether a positive response to tolvaptan (a non-peptide orally available arginine vasopressin V2 receptor antagonist) therapy would be a good prognostic factor for cirrhotic patients with ascites. It was noted that tolvaptan therapy was effective in 61.6% of cirrhotic patients. Factors that were independently associated with the overall survival (OS) were male, tolvaptan responder, and dosage of furosemide < 40 mg/day. The multivariate analysis showed that C-reactive protein < 0.9 mg/dL, and furosemide dosage < 40 mg/day were independently correlated with the tolvaptan response. Overall, it was concluded that the therapeutic response to tolvaptan was related to longer survival in cirrhosis patients complicated with ascites.